<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118544</article-id><article-id pub-id-type="publisher-id">ACM-44801</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_24723119.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  男性乳腺癌的影像学研究进展
  Advances in Imaging Research of Male Breast Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蔡</surname><given-names>文清</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>霍</surname><given-names>善棋</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>廖</surname><given-names>发超</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>志明</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姚</surname><given-names>虹</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>云南省第一人民医院放射科，云南 昆明</addr-line></aff><aff id="aff2"><addr-line>大理大学临床医学院，云南 大理；云南省第一人民医院放射科，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3709</fpage><lpage>3713</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  男性乳腺癌(male breast cancer, MBC)为一种罕见的恶性肿瘤，目前对MBC的研究还不够深入，其诊断与治疗方法较多依赖于女性乳腺癌的研究。MBC有着不同于女性乳腺癌的发病年龄、临床症状、内分泌状况以及病理、分子分型，同时在影像学检查上也存在差别。本文将就男性乳腺癌的危险因素、临床病理学、影像学检查及筛查诊断建议等进行综述。
   Male breast cancer (MBC) is a rare malignant tumor. At present, the research on MBC is not deep enough, and its diagnosis and treatment mainly rely on the study of female breast cancer. The age of onset, clinical symptoms, endocrine status, pathological and molecular classification of MBC are different from those of female breast cancer, and there are also differences in imaging examination. This article will review the risk factors, clinicopathology, imaging examination and diagnostic recommendations of male breast cancer.
 
</p></abstract><kwd-group><kwd>男性乳腺癌，乳腺X线检查，乳腺超声，临床病理, Male Breast Cancer</kwd><kwd> Mammography</kwd><kwd> Breast Ultrasound</kwd><kwd> Clinical Pathology</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>男性乳腺癌(male breast cancer, MBC)为一种罕见的恶性肿瘤，目前对MBC的研究还不够深入，其诊断与治疗方法较多依赖于女性乳腺癌的研究。MBC有着不同于女性乳腺癌的发病年龄、临床症状、内分泌状况以及病理、分子分型，同时在影像学检查上也存在差别。本文将就男性乳腺癌的危险因素、临床病理学、影像学检查及筛查诊断建议等进行综述。</p></sec><sec id="s2"><title>关键词</title><p>男性乳腺癌，乳腺X线检查，乳腺超声，临床病理</p></sec><sec id="s3"><title>Advances in Imaging Research of Male Breast Cancer<sup> </sup></title><p>Wenqing Cai<sup>1,2</sup>, Shanqi Huo<sup>2</sup>, Fachao Liao<sup>2</sup>, Zhiming Chen<sup>2</sup>, Hong Yao<sup>2*</sup></p><p><sup>1</sup>Clinical Medical College of Dali University, Dali Yunnan</p><p><sup>2</sup>Department of Radiology, Yunnan First People’s Hospital, Kunming Yunnan</p><p><img src="//html.hanspub.org/file/61-1572511x5_hanspub.png?20210827085529520" /></p><p>Received: Jul. 23<sup>rd</sup>, 2021; accepted: Aug. 19<sup>th</sup>, 2021; published: Aug. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/61-1572511x6_hanspub.png?20210827085529520" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Male breast cancer (MBC) is a rare malignant tumor. At present, the research on MBC is not deep enough, and its diagnosis and treatment mainly rely on the study of female breast cancer. The age of onset, clinical symptoms, endocrine status, pathological and molecular classification of MBC are different from those of female breast cancer, and there are also differences in imaging examination. This article will review the risk factors, clinicopathology, imaging examination and diagnostic recommendations of male breast cancer.</p><p>Keywords:Male Breast Cancer, Mammography, Breast Ultrasound, Clinical Pathology</p><disp-formula id="hanspub.44801-formula29"><graphic xlink:href="//html.hanspub.org/file/61-1572511x7_hanspub.png?20210827085529520"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/61-1572511x8_hanspub.png?20210827085529520" /> <img src="//html.hanspub.org/file/61-1572511x9_hanspub.png?20210827085529520" /></p></sec><sec id="s5"><title>1. 引言</title><p>男性乳腺癌(male breast cancer, MBC)在所有种类的乳腺癌和男性的恶性肿瘤中所占比例均不到1% [<xref ref-type="bibr" rid="hanspub.44801-ref1">1</xref>]。与女性乳腺癌(Female Breast Cancer, FBC)相似，近年来MBC的发病率也有增加的趋势，已从过去的约1/10万人，增长为1.2/10万人 [<xref ref-type="bibr" rid="hanspub.44801-ref2">2</xref>]。但目前对于MBC的危险因素、检查方法和治疗的临床研究相对较少，以至于男性乳腺癌的检出率、治疗和预后不够理想。MBC的早期影像学检查手段主要包括乳腺X线摄影和超声，存在局部晚期或远处转移时则会考虑其他影像检查方式(CT、PET-CT、MRI)的应用。</p></sec><sec id="s6"><title>2. 男性乳腺癌的危险因素</title><p>目前对于MBC的危险因素还在探索和讨论之中，国外研究认为，其危险因素包括遗传易感性、雌激素–睾酮比率的改变、辐射暴露以及职业危害。抑癌基因BRCA突变携带者的患肿瘤风险明显增加，其中，BRCA2突变携带者患乳腺癌的终生风险为最高可达到7%左右，为普通人群的80倍以上 [<xref ref-type="bibr" rid="hanspub.44801-ref3">3</xref>]。患有内分泌疾病克氏综合征的男性有睾丸发育不良、睾酮浓度低和促性腺激素增加等症状，以及导致睾酮缺乏的其他疾病，包括未降睾丸、先天性腹股沟疝、睾丸炎症及损伤等，都与MBC风险增加相关。男性肥胖以及所导致的男性胸部发育也与乳腺癌有一定关连。暴露于治疗性电离辐射以及长期在高温环境中工作的男性患乳腺癌的风险也明显增高 [<xref ref-type="bibr" rid="hanspub.44801-ref4">4</xref>]。</p></sec><sec id="s7"><title>3. 男性乳腺癌的临床病理学</title><p>MBC最常见的组织病理学类型是浸润性导管癌，女性常见的其他特殊类型的乳腺癌，也都可能发生在男性乳腺癌中。由于男性缺乏乳腺小叶组织，因此浸润性小叶癌的发生率较低，MBC只有1.5%是小叶癌，而FBC中约12%的癌症是小叶癌。约90%的男性乳腺癌表达雌激素受体，81%表达孕激素受体，可见男性乳腺癌患者的激素表达水平较女性高。而HER-2阳性率低于女性乳腺癌三倍左右 [<xref ref-type="bibr" rid="hanspub.44801-ref5">5</xref>]。MBC拥有低的组织学分级和高的雌激素受体/孕激素受体阳性表达率，这一特点与雌激素受体/孕激素受体阳性的绝经后的女性乳腺癌相似，对内分泌治疗反应好 [<xref ref-type="bibr" rid="hanspub.44801-ref6">6</xref>]。</p><p>MBC与FBC的主要区别是肿瘤原发部位，男性乳腺癌多源于乳腺中央导管，多发生于乳晕区，女性乳腺癌多源于乳腺终末外周乳导管 [<xref ref-type="bibr" rid="hanspub.44801-ref7">7</xref>]。因此无痛的、可触及的乳晕后肿块是MBC最常见的临床征象。由于男性乳房与女性的解剖学差异，腺管到乳头之间的距离较短，局部区域淋巴网发达，因而MBC早期易侵犯乳头及大乳管，并且更容易累及皮肤和区域淋巴结，出现皮肤增厚和乳头凹陷，乳内、腋窝淋巴结转移也更常见 [<xref ref-type="bibr" rid="hanspub.44801-ref8">8</xref>]。</p></sec><sec id="s8"><title>4. 男性乳腺癌的影像学诊断</title><sec id="s8_1"><title>4.1. 乳腺钼靶X线摄影</title><p>目前，乳腺钼靶X线摄影是诊断乳腺疾病的无创性检查手段，具有图像分辨率高、诊断准确率高、检查价格相对低廉、对患者辐射相对较小等优点。男性的乳房钼靶X光检查更多地被用作诊断及评估严重程度的工具，而不用作广泛筛查，但乳腺钼靶X线摄影在男性乳腺良恶性疾病的鉴别诊断中起着关键作用，有着其特有的优势。</p><p>男性乳腺癌在钼靶X线摄影上的表现与女性乳腺癌相似，大部分浸润性癌在乳晕下区域表现为高密度的不规则肿块，边缘存在毛刺及分叶 [<xref ref-type="bibr" rid="hanspub.44801-ref9">9</xref>]。微钙化在男性导管原位癌中较多见，在其他病理类型中的出现概率约为四分之一。乳头状癌常伴有囊肿或扩张的导管，表现为混合了实性和囊性形态特征的复杂囊肿。Adibelli等，在研究中发现乳房X光检查的敏感度和特异度分别为69%和87%，这也就是说乳腺X光钼靶检查在69%的已知恶性病例中发现了恶性肿瘤，并在87%的已知良性病例中排除了恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.44801-ref10">10</xref>]。超过99%的男性乳腺癌为单侧，Yoon等，评估单、双侧钼靶X线摄影在男性单侧乳腺症状患者中的应用价值，结果证实在男性单侧乳腺症状患者中，单侧钼靶X线摄影的诊断性能与双侧钼靶摄影相当，单侧乳房X线检查还具有减少辐射暴露的优势 [<xref ref-type="bibr" rid="hanspub.44801-ref11">11</xref>]。同时，钼靶X线摄影在鉴别乳腺癌和男性乳房发育症方面也有着其独特的优势及准确率 [<xref ref-type="bibr" rid="hanspub.44801-ref12">12</xref>]。</p></sec><sec id="s8_2"><title>4.2. 乳腺超声</title><p>乳腺超声的检测费用低廉，仪器操作简便，并且可在短时间内重复检查，因其独特的优势作为目前针对乳腺疾病的常规检查方法。同时，超声对于乳腺癌的诊断价值也是值得肯定的，对于一些其他影像检查无法发现的男性乳腺癌，其异常结果可仅仅在超声检查中被发现 [<xref ref-type="bibr" rid="hanspub.44801-ref13">13</xref>]。</p><p>在国内一项研究中，回顾分析了MBC患者的声像图特征，显示其二维超声图像表现为低回声的不规则肿块影，边界呈浸润性，后方回声衰减，可见沙粒样钙化，多数肿块CDFI显示肿瘤的血运丰富，由此可见超声对男性乳腺癌患者的早期诊断有重要价值 [<xref ref-type="bibr" rid="hanspub.44801-ref14">14</xref>]。另一项研究则表明了乳腺癌发生与脂肪密切相关，需要进一步阐明乳腺癌发生率与脂肪层厚度的关系 [<xref ref-type="bibr" rid="hanspub.44801-ref15">15</xref>]。</p></sec><sec id="s8_3"><title>4.3. PET/CT</title><p>PET/CT检查是分子功能影像和解剖影像两种方法的融合，作为一项非侵入性的检查方法在乳腺癌的诊断中具有广泛的应用前景。目前临床上所做多为<sup>18</sup>F-氟代脱氧葡萄糖(Fluorine-18 Fluorodeoxyglucose, FDG)显像，通过观察病变组织对葡萄糖的利用率进行疾病诊断，目前多用于检测乳腺癌的腋外淋巴结及远处转移。</p><p>在女性中，<sup>18</sup>F-FDG的亲和力取决于肿瘤的生物学特性，其摄取率受肿瘤雌激素受体(&#177;)的影响。Groheux等，评估<sup>18</sup>F-FDG-PET/CT在识别男性乳腺癌患者远处转移方面的整体表现，结果显示，虽然所调查病例全部为雌激素受体阳性，但<sup>18</sup>F-FDG-PET/CT对肿瘤原发灶和转移灶的诊断依然具有很高的敏感性，证明<sup>18</sup>F-FDG-PET/CT对男性乳腺癌患者的分期、再分期和疗效具有重要价值 [<xref ref-type="bibr" rid="hanspub.44801-ref16">16</xref>]。Polverari等，在对一名男性前列腺癌盆腔淋巴结转移患者进行<sup>68</sup>Ga-PSMA-11PET/CT检测后，意外发现了位于左侧的乳腺癌病灶，表明<sup>68</sup>Ga-PSMA-11PET/CT有能力可以发现前列腺癌以外的病变 [<xref ref-type="bibr" rid="hanspub.44801-ref17">17</xref>]。</p></sec><sec id="s8_4"><title>4.4. 筛查和诊断建议</title><p>MBC的筛查和诊断意见源于FBC的研究推断，这是因为正式的建议和指南需要大型临床试验，而MBC的罕见性排除了大型临床试验。根据美国癌症协会(American Cancer Society)发布的最新癌症筛查指南，MBC筛查的建议包括乳房X线检查、临床乳房检查(CBE)、乳房自检，但不推荐将CBE作为筛查唯一方法。对于高危人群给出了明确的筛查指南，如表1。在诊断上，医生面临的主要挑战是提高良、恶性病变的区分(例如多数病人中存在男性乳房发育症)，及提高乳腺肿瘤诊断的特异性 [<xref ref-type="bibr" rid="hanspub.44801-ref18">18</xref>]。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Screening recommendations for men at high risk of breast cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >每月的乳房自检</th></tr></thead><tr><td align="center" valign="middle" >半年一次的临床乳房检查</td></tr><tr><td align="center" valign="middle" >如果存在男性乳房发育症和/或乳房密度异常，则先做基线乳房X线检查，之后每年进行乳房X线检查</td></tr><tr><td align="center" valign="middle" >考虑基因检测，告知家庭成员风险和基因检测选项</td></tr><tr><td align="center" valign="middle" >风险增加的类别包括有乳腺癌家族史(FBC和MBC)、遗传易感性和有MBC个人病史的男性</td></tr></tbody></table></table-wrap><p>表1. 乳腺癌高危男性的筛查建议</p></sec></sec><sec id="s9"><title>5. 结语</title><p>综上所述，男性乳腺癌(MBC)的发病率相比于女性乳腺癌较低，但其存在检出率低、诊断延迟、预后差、死亡率高等特点。50%以上的MBC到确诊时，已经进展到II期或更高阶段，而FBC的这一比例仅为35%。这主要是由于MBC较罕见，因此患者对MBC的重视程度不高及医生容易忽略这一诊断。MBC缺乏常规筛查也可能是原因之一，X线钼靶和超声在疾病早期诊断及良恶性鉴别中发挥着重要作用，如果能对疾病危险因素提高认识，遵循对高危人群的筛查方案及基因检测，就有可能做到早诊早治，最终提高MBC患者预后。此外，在针对MBC的治疗上，更多强调FBC与MBC之间的差异，提倡规范化，个体化治疗，努力提高男性乳腺癌的治愈率和改善预后。</p></sec><sec id="s10"><title>文章引用</title><p>蔡文清,霍善棋,廖发超,陈志明,姚 虹. 男性乳腺癌的影像学研究进展Advances in Imaging Research of Male Breast Cancer[J]. 临床医学进展, 2021, 11(08): 3709-3713. https://doi.org/10.12677/ACM.2021.118544</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44801-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30.  
&lt;br&gt;https://doi.org/10.3322/caac.21590</mixed-citation></ref><ref id="hanspub.44801-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Speirs, V. and Shaaban, A.M. (2009) The Rising Incidence of Male Breast Cancer. Breast Cancer Research and Treatment, 115, 429-430. &lt;br&gt;https://doi.org/10.1007/s10549-008-0053-y</mixed-citation></ref><ref id="hanspub.44801-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Levy-Lahad, E. and Friedman, E. (2007) Cancer Risks among BRCA1 and BRCA2 Mutation Carriers. British Journal of Cancer, 96, 11-15. &lt;br&gt;https://doi.org/10.1038/sj.bjc.6603535</mixed-citation></ref><ref id="hanspub.44801-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Brinton, L.A., Richesson, D.A., Gierach, G.L., Lacey, J.V., Park, Y., Hollenbeck, A.R. and Schatzkin, A. (2008) Prospective Evaluation of Risk Factors for Male Breast Cancer. Journal of the National Cancer Institute, 100, 1477-1481.  
&lt;br&gt;https://doi.org/10.1093/jnci/djn329</mixed-citation></ref><ref id="hanspub.44801-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ottini, L., Palli, D., Rizzo, S., Federico, M., Bazan, V. and Russo, A. (2010) Male Breast Cancer. Critical Reviews in Oncology/Hematology, 73, 141-155. &lt;br&gt;https://doi.org/10.1016/j.critrevonc.2009.04.003</mixed-citation></ref><ref id="hanspub.44801-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Liu, M., Wang, Q., Liu, B., Gao, L., Wu, D., Yang, S., Liu, B. and Dong, L. (2015) Male Breast Carcinoma: Radiotherapy Contributed to Favorable Local Control in Two Cases and Related Literature Review. European Journal of Medical Research, 20, Article No. 94. &lt;br&gt;https://doi.org/10.1186/s40001-015-0173-x</mixed-citation></ref><ref id="hanspub.44801-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Mathew, J., Perkins, G.H., Stephens, T., Middleton, L.P. and Yang, W.T. (2008) Primary Breast Cancer in Men: Clinical, Imaging, and Pathologic Findings in 57 Patients. American Journal of Roentgenology, 191, 1631-1639.  
&lt;br&gt;https://doi.org/10.2214/AJR.08.1076</mixed-citation></ref><ref id="hanspub.44801-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gao, Y., Heller, S.L. and Moy, L. (2018) Male Breast Cancer in the Age of Genetic Testing: An Opportunity for Early Detection, Tailored Therapy, and Surveillance. Radiographics, 38, 1289-1311. &lt;br&gt;https://doi.org/10.1148/rg.2018180013</mixed-citation></ref><ref id="hanspub.44801-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Shi, A.A., Georgian-Smith, D., Cornell, L.D., Rafferty, E.A., Staffa, M., Hughes, K. and Kopans, D.B. (2005) Radiological Reasoning: Male Breast Mass with Calcifications. American Journal of Roentgenology, 185, S205-S210.  
&lt;br&gt;https://doi.org/10.2214/AJR.05.1078</mixed-citation></ref><ref id="hanspub.44801-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Adibelli, Z.H., Oztekin, O., Postaci, H. and Uslu, A. (2009) The Diagnostic Accuracy of Mammography and Ultrasound in the Evaluation of Male Breast Disease: A New Algorithm. Breast Care (Basel), 4, 255-259.  
&lt;br&gt;https://doi.org/10.1159/000226284</mixed-citation></ref><ref id="hanspub.44801-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yoon, B., Chae, E.Y., Cha, J.H., Shin, H.J., Choi, W.J. and Kim, H.H. (2020) Male Patients with Unilateral Breast Symptoms: An Optimal Imaging Approach. European Radiology, 30, 4242-4250.  
&lt;br&gt;https://doi.org/10.1007/s00330-020-06828-3</mixed-citation></ref><ref id="hanspub.44801-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Patterson, S.K., Helvie, M.A., Aziz, K. and Nees, A.V. (2006) Outcome of Men Presenting with Clinical Breast Problems: The Role of Mammography and Ultrasound. The Breast Journal, 12, 418-423.  
&lt;br&gt;https://doi.org/10.1111/j.1075-122X.2006.00298.x</mixed-citation></ref><ref id="hanspub.44801-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Golshan, M., Fung, B.B., Wolfman, J., Rademaker, A. and Morrow, M. (2003) The Effect of Ipsilateral Whole Breast Ultrasonography on the Surgical Management of Breast Carcinoma. The American Journal of Surgery, 186, 391-396.  
&lt;br&gt;https://doi.org/10.1016/S0002-9610(03)00280-0</mixed-citation></ref><ref id="hanspub.44801-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">刘畅, 刘晓婷, 高岿然, 于韬. 老年男性乳腺癌27例超声诊断分析[J]. 肿瘤学杂志, 2018, 24(9): 934-935.</mixed-citation></ref><ref id="hanspub.44801-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">王勇, 白玲, 毛京宁, 陈伟, 范雪, 张彦, 陈翠京. 男性乳腺癌超声影像特征分析[J]. 临床荟萃, 2012, 27(5): 382-385.</mixed-citation></ref><ref id="hanspub.44801-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Groheux, D., Hindié, E., Marty, M., Espié, M., Rubello, D., Vercellino, L., Bousquet, G., Ohnona, J., Toubert, M.E., Merlet, P. and Misset, J.L. (2014) 18F-FDG-PET/CT in Staging, Restaging, and Treatment Response Assessment of Male Breast Cancer. European Journal of Radiology, 83, 1925-1933. &lt;br&gt;https://doi.org/10.1016/j.ejrad.2014.05.037</mixed-citation></ref><ref id="hanspub.44801-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Polverari, G., Ceci, F., Calderoni, L., Cervati, V., Farolfi, A., Castellucci, P. and Fanti, S. (2019) Male Breast Cancer Detected by Ga-PSMA-11 PET/CT in a Patient with Prostate Cancer with Pelvic Lymph Node Metastasis. Clinical Genitourinary Cancer, 17, 154-156. &lt;br&gt;https://doi.org/10.1016/j.clgc.2018.11.020</mixed-citation></ref><ref id="hanspub.44801-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Johansen, T.K.A., Morisy, L.R., Osbahr, A.J., et al. (2010) Male Breast Cancer: Risk Factors, Diagnosis, and Management (Review). Oncology Reports, 24, 1115-1120. &lt;br&gt;https://doi.org/10.3892/or_00000962</mixed-citation></ref></ref-list></back></article>